ERBB2 and cancer: Over the past two decades, remarkable progress has been made in the development of HER2-positive cancer treatments, with a significant number of drugs targeting the HER2 receptor moving into clinical practice, including monoclonal antibodies, inhibitors of tyrosine kinase, antibody–drug conjugates and adoptive T-cell therapies, as well as vaccines [23].